Glycation in Alzheimer’s Disease and Type 2 Diabetes: The Prospect of Dual Drug Approaches for Therapeutic Interventions
<p dir="ltr">As global life expectancy increases, the prevalence of neurodegenerative diseases like Alzheimer’s disease (AD) continues to rise. Since therapeutic options are minimal, a deeper understanding of the pathophysiology is essential for improved diagnosis and treatments. AD...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , |
| منشور في: |
2025
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513533642801152 |
|---|---|
| author | Sama Ayoub (15430987) |
| author2 | Maryam Arabi (3927509) Yousef Al-Najjar (14147835) Ibrahim Laswi (14787432) Tiago F. Outeiro (191379) Ali Chaari (827168) |
| author2_role | author author author author author |
| author_facet | Sama Ayoub (15430987) Maryam Arabi (3927509) Yousef Al-Najjar (14147835) Ibrahim Laswi (14787432) Tiago F. Outeiro (191379) Ali Chaari (827168) |
| author_role | author |
| dc.creator.none.fl_str_mv | Sama Ayoub (15430987) Maryam Arabi (3927509) Yousef Al-Najjar (14147835) Ibrahim Laswi (14787432) Tiago F. Outeiro (191379) Ali Chaari (827168) |
| dc.date.none.fl_str_mv | 2025-05-22T09:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1007/s12035-025-05051-9 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Glycation_in_Alzheimer_s_Disease_and_Type_2_Diabetes_The_Prospect_of_Dual_Drug_Approaches_for_Therapeutic_Interventions/30455201 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Immunology Medical biochemistry and metabolomics Neurosciences Pharmacology and pharmaceutical sciences Health sciences Public health Alzheimer’s disease Type 2 diabetes Advanced glycation end products (AGEs) Dual drugs |
| dc.title.none.fl_str_mv | Glycation in Alzheimer’s Disease and Type 2 Diabetes: The Prospect of Dual Drug Approaches for Therapeutic Interventions |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p dir="ltr">As global life expectancy increases, the prevalence of neurodegenerative diseases like Alzheimer’s disease (AD) continues to rise. Since therapeutic options are minimal, a deeper understanding of the pathophysiology is essential for improved diagnosis and treatments. AD is marked by the aggregation of Aβ proteins, tau hyperphosphorylation, and progressive neuronal loss, though its precise origins remain poorly understood. Meanwhile, type 2 diabetes mellitus (T2DM) is characterized by chronic hyperglycemia, leading to the formation of advanced glycation end products (AGEs), which are implicated in tissue damage and neurotoxicity. These AGEs can be resistant to proteolysis and, therefore, accumulate, exacerbating AD pathology and accelerating neurodegeneration. Insulin resistance, a hallmark of T2DM, further complicates AD pathogenesis by promoting tau hyperphosphorylation and Aβ plaque accumulation. Additionally, gut microbiome dysbiosis in T2DM fosters AGE accumulation and neuroinflammation, underscoring the intricate relationship between metabolic disorders, gut health, and neurodegenerative processes. This complex interplay presents both a challenge and a potential avenue for therapeutic intervention. Emerging evidence suggests that antidiabetic medications may offer cognitive benefits in AD, as well as in other neurodegenerative conditions, pointing to a shared pathophysiology. Thus, we posit that targeting AGEs, insulin signaling, and gut microbiota dynamics presents promising opportunities for innovative treatment approaches in AD and T2DM.</p><h2>Other Information</h2><p dir="ltr">Published in: Molecular Neurobiology<br>License: <a href="https://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1007/s12035-025-05051-9" target="_blank">https://dx.doi.org/10.1007/s12035-025-05051-9</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_3486624ef0a922301154e3c16f1a7738 |
| identifier_str_mv | 10.1007/s12035-025-05051-9 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/30455201 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Glycation in Alzheimer’s Disease and Type 2 Diabetes: The Prospect of Dual Drug Approaches for Therapeutic InterventionsSama Ayoub (15430987)Maryam Arabi (3927509)Yousef Al-Najjar (14147835)Ibrahim Laswi (14787432)Tiago F. Outeiro (191379)Ali Chaari (827168)Biomedical and clinical sciencesImmunologyMedical biochemistry and metabolomicsNeurosciencesPharmacology and pharmaceutical sciencesHealth sciencesPublic healthAlzheimer’s diseaseType 2 diabetesAdvanced glycation end products (AGEs)Dual drugs<p dir="ltr">As global life expectancy increases, the prevalence of neurodegenerative diseases like Alzheimer’s disease (AD) continues to rise. Since therapeutic options are minimal, a deeper understanding of the pathophysiology is essential for improved diagnosis and treatments. AD is marked by the aggregation of Aβ proteins, tau hyperphosphorylation, and progressive neuronal loss, though its precise origins remain poorly understood. Meanwhile, type 2 diabetes mellitus (T2DM) is characterized by chronic hyperglycemia, leading to the formation of advanced glycation end products (AGEs), which are implicated in tissue damage and neurotoxicity. These AGEs can be resistant to proteolysis and, therefore, accumulate, exacerbating AD pathology and accelerating neurodegeneration. Insulin resistance, a hallmark of T2DM, further complicates AD pathogenesis by promoting tau hyperphosphorylation and Aβ plaque accumulation. Additionally, gut microbiome dysbiosis in T2DM fosters AGE accumulation and neuroinflammation, underscoring the intricate relationship between metabolic disorders, gut health, and neurodegenerative processes. This complex interplay presents both a challenge and a potential avenue for therapeutic intervention. Emerging evidence suggests that antidiabetic medications may offer cognitive benefits in AD, as well as in other neurodegenerative conditions, pointing to a shared pathophysiology. Thus, we posit that targeting AGEs, insulin signaling, and gut microbiota dynamics presents promising opportunities for innovative treatment approaches in AD and T2DM.</p><h2>Other Information</h2><p dir="ltr">Published in: Molecular Neurobiology<br>License: <a href="https://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1007/s12035-025-05051-9" target="_blank">https://dx.doi.org/10.1007/s12035-025-05051-9</a></p>2025-05-22T09:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1007/s12035-025-05051-9https://figshare.com/articles/journal_contribution/Glycation_in_Alzheimer_s_Disease_and_Type_2_Diabetes_The_Prospect_of_Dual_Drug_Approaches_for_Therapeutic_Interventions/30455201CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/304552012025-05-22T09:00:00Z |
| spellingShingle | Glycation in Alzheimer’s Disease and Type 2 Diabetes: The Prospect of Dual Drug Approaches for Therapeutic Interventions Sama Ayoub (15430987) Biomedical and clinical sciences Immunology Medical biochemistry and metabolomics Neurosciences Pharmacology and pharmaceutical sciences Health sciences Public health Alzheimer’s disease Type 2 diabetes Advanced glycation end products (AGEs) Dual drugs |
| status_str | publishedVersion |
| title | Glycation in Alzheimer’s Disease and Type 2 Diabetes: The Prospect of Dual Drug Approaches for Therapeutic Interventions |
| title_full | Glycation in Alzheimer’s Disease and Type 2 Diabetes: The Prospect of Dual Drug Approaches for Therapeutic Interventions |
| title_fullStr | Glycation in Alzheimer’s Disease and Type 2 Diabetes: The Prospect of Dual Drug Approaches for Therapeutic Interventions |
| title_full_unstemmed | Glycation in Alzheimer’s Disease and Type 2 Diabetes: The Prospect of Dual Drug Approaches for Therapeutic Interventions |
| title_short | Glycation in Alzheimer’s Disease and Type 2 Diabetes: The Prospect of Dual Drug Approaches for Therapeutic Interventions |
| title_sort | Glycation in Alzheimer’s Disease and Type 2 Diabetes: The Prospect of Dual Drug Approaches for Therapeutic Interventions |
| topic | Biomedical and clinical sciences Immunology Medical biochemistry and metabolomics Neurosciences Pharmacology and pharmaceutical sciences Health sciences Public health Alzheimer’s disease Type 2 diabetes Advanced glycation end products (AGEs) Dual drugs |